Blocking CXCL5 signaling pathway using CXCR2 antagonists significantly attenuates microglia activation and thus reduces neuroinflammation after cerebral ischemia.Lin-Yu Wang et al. showed that mediating SDF-1 expression in astrocytes leads to downregulation of CXCL5 expression and is a viable treatment for sublethal ischemia (Wang et al., 2016c).Chen F suggested that long noncoding RNA SNHG15 is a new target for ischemic stroke therapy by upregulating CXCL13, thereby reducing apoptosis (Guo et al., 2020b). Here, CXCL13 is linked to ischemic stroke.